RB042
Pre-clinical- Indications
- Inflammatory lung disease
Company intelligence / Profile preview
RAGE Biotech
Australiaragebiotech.com ↗
- Ownership
- Private
- Employees
- ~1
- Development stage
- Preclinical
01
Overview
Lead medication RBr042 is in final stages of preclinical development as a nebulized treatment for chronic lung inflammation, preparing for Phase 1 clinical trials
- Therapeutic areas
- NephrologyPulmonologyImmunologyGastroenterologyNeurology
- Modalities
- RNA therapeuticspeptide technologiessplice-switching oligonucleotide (SSO)
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Beyond the preview
Go deeper on RAGE Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RAGE Biotech.